S&P Lowers Opinion of Credit Suisse Group's Stock

Plus: analyst comments about Eli Lilly, Gateway, Alltel's wireline spinoff deal with Valor, Intel's guidance revision, and Merck's disagreement with a New England Journal of Medicine editorial that says the drug company withheld data about Vioxx.

Credit Suisse Group (CSR ): Cuts to 3 STARS (hold) from 4 STARS (buy)

To continue reading this article you must be a Bloomberg Professional Service Subscriber.